Jan 27 (Reuters) - SAGE Therapeutics Inc SAGE.O:
SAGE THERAPEUTICS BOARD OF DIRECTORS INITIATES REVIEW OF STRATEGIC ALTERNATIVES AND REJECTS BIOGEN’S UNSOLICITED ACQUISITION PROPOSAL
SAGE THERAPEUTICS INC - REJECTS BIOGEN'S $7.22 PER SHARE ACQUISITION PROPOSAL
SAGE THERAPEUTICS INC - CONCLUDES PROPOSAL FROM BIOGEN SIGNIFICANTLY UNDERVALUES CO
Source text: ID:nBw2Dlncha
Further company coverage: SAGE.O
(Reporting by Siddhi Mahatole)
((SiddhiPrabhanjan.Mahatole@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.